IMedis Overview
IMedis is developing a comprehensive quality management system for radiology departments. The AI-driven cloud-based solution aggregates and analyzes data from the PACS and RIS. By addressing failure points throughout the radiology workflow, IMedis aims to reduce risk, improve financial efficacy, and create new business opportunities. Duali-Q, IMedis's first commercially available module, allows management and follow-up of errors of omission in CT scans of the chest and the abdomen. Duali-Q was proven to increase detection rates of life-threatening diseases by 13% in a recent study and is now in use by teaching hospitals in the United States, United Kingdom, and Israel.
Cumulative Funding Raised Over Time ($)
$1.0MApr 2018
$2.3MJan 2020
$3.7MOct 2021
Latest News
growth-positive
צפו: הפיתוח הישראלי שמסייע לזהות מחלת סרטן בשלב מוקדם
IMedis, a company that utilizes AI technologies for early disease detection, aims to optimize diagnostic and preventive medicine. The companys solution, Duali-Q, is an AI-based system for quality control in radiology departments. It analyzes medical images and reports in real-time, alerting healthcare professionals to significant findings that may have been missed. IMedis is focused on recruiting new customers and expanding its operations. The article highlights the potential of AI in revolutionizing the healthcare industry and improving patient outcomes.
CustomersExpand
growth-positive
הסטארט-אפ הישראלי שמסייע באבחון מוקדם של מחלת הסרטן
IMedis, an Israeli healthcare company, has developed an artificial intelligence (AI) system, Duali-Q, to improve early diagnosis of life-threatening diseases. The system uses advanced algorithms to identify early signs of disease in CT scans, cross-referencing this with the medical report written by the doctor and alerting in real time if a significant finding is not reported. IMedis has successfully completed a trial at UC San Diego and is beginning commercial pilots with leading hospitals in the US, UK, and Israel. The company is also in advanced talks with several major hospitals in the UK.
CustomersPartnersInvestment
growth-positive
Israel-based IMedis receives CE approval for radiology scans in EU
Israeli medical system company IMedis has received CE approval for its AI-based quality control system for radiology departments. The approval allows markets to purchase its system, which can accurately identify findings that may have been missed by radiologists. The system can help discover early findings without symptoms that may lead to cancer. IMedis operates as part of Teva and Philips investment platform, Sanara Ventures. The company has raised $2.3 million, $1.3 million of which was raised through crowdfunding platform ExitValley. IMedis is currently seeking FDA approval.
Investment
growth-positive
Medical Device Startup IMedis Raises $1.3 Million in Crowdfunding Campaign
Israel-based medical device startup IMedis AI Ltd. has raised $1.3 million through a crowdfunding campaign on Israeli website ExitValley. IMedis develops AI technology for analyzing medical images and documents to detect discrepancies and unreported findings, aiding in the early detection of cancer, heart diseases, and vascular diseases. The company has raised a total of $2.3 million to date.
Investment
growth-positive
האלגוריתם שיזהה מראש את הסרטן: הסטארטאפ IMedis גייס 1.3 מיליון דולר
Israeli company IMedis has raised $1.3 million in funding for its artificial intelligence-based system for early detection of cancer, heart disease, and blood diseases. The system combines image analysis with text analysis to alert radiologists in real-time to early signs of diseases that may not be evident in medical reports. IMedis aims to support radiologists in identifying specific clinical indications that may indicate cancer, heart disease, or blood diseases. The company faces competition from other AI-based medical imaging companies such as AIdoc, Zebra Medical, Viz.ai, and DiA Imaging. IMedis recently completed a clinical trial at UC San Diego Hospital, demonstrating the systems ability to improve patient care and reduce healthcare costs. The company has filed for a patent and is awaiting FDA approval.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.7M |
| Last funding | $1.4M |
| Stage | Pre-Seed |
| Rounds | 3 |
| Investors | 2 |
Team Members
3
Employees: 500+
Web & Social Links
| Website | www.imedis.ai/ |
| Careers | Careers page |
Locations
Rehovot, Israel
New York, NY, USA
Photos & Videos
3 item(s)
IMedis Business
Business models
B2B
Product stage
Released
Employees
500+
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Artificial IntelligenceMachine LearningComputer VisionNatural Language ProcessingTags (15)
deep-learningmachine-visionradiologynatural-language-processingimaginghospitalsartificial-intelligencect-scanhealthcare-providersdigital-healthcaremachine-learningcardiovascularquality-controlpatent-pendingqaGeographic Markets
EuropeAmericasOceaniaIMedis Financials
$3.7M
Total funding
Undisclosed
Capital raised
$1.4M
Last funding
Pre-Seed
Funding stage
3
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$1.0MApr 2018
$2.3MJan 2020
$3.7MOct 2021
Private Equity Funding
Convertible Debt
Oct 2021
$1.4M
Equity crowdfunding
Jan 2020
$1.3M
ExitValley
Pre-Seed
Apr 2018
$1M
Sanara Ventures (Lead)
IMedis Lifecycle
Cumulative Funding Raised Over Time
$1.0MApr 2018
$2.3MJan 2020
$3.7MOct 2021
All Events
Convertible Debt
Oct 2021
$1.4M
Equity crowdfunding
Jan 2020
$1.3M
ExitValley
Pre-Seed
Apr 2018
$1M
Sanara Ventures (Lead)
IMedis News
5 articles
growth-positive
צפו: הפיתוח הישראלי שמסייע לזהות מחלת סרטן בשלב מוקדם
IMedis, a company that utilizes AI technologies for early disease detection, aims to optimize diagnostic and preventive medicine. The companys solution, Duali-Q, is an AI-based system for quality control in radiology departments. It analyzes medical images and reports in real-time, alerting healthcare professionals to significant findings that may have been missed. IMedis is focused on recruiting new customers and expanding its operations. The article highlights the potential of AI in revolutionizing the healthcare industry and improving patient outcomes.
CustomersExpand
growth-positive
הסטארט-אפ הישראלי שמסייע באבחון מוקדם של מחלת הסרטן
IMedis, an Israeli healthcare company, has developed an artificial intelligence (AI) system, Duali-Q, to improve early diagnosis of life-threatening diseases. The system uses advanced algorithms to identify early signs of disease in CT scans, cross-referencing this with the medical report written by the doctor and alerting in real time if a significant finding is not reported. IMedis has successfully completed a trial at UC San Diego and is beginning commercial pilots with leading hospitals in the US, UK, and Israel. The company is also in advanced talks with several major hospitals in the UK.
CustomersPartnersInvestment
growth-positive
Israel-based IMedis receives CE approval for radiology scans in EU
Israeli medical system company IMedis has received CE approval for its AI-based quality control system for radiology departments. The approval allows markets to purchase its system, which can accurately identify findings that may have been missed by radiologists. The system can help discover early findings without symptoms that may lead to cancer. IMedis operates as part of Teva and Philips investment platform, Sanara Ventures. The company has raised $2.3 million, $1.3 million of which was raised through crowdfunding platform ExitValley. IMedis is currently seeking FDA approval.
Investment
growth-positive
Medical Device Startup IMedis Raises $1.3 Million in Crowdfunding Campaign
Israel-based medical device startup IMedis AI Ltd. has raised $1.3 million through a crowdfunding campaign on Israeli website ExitValley. IMedis develops AI technology for analyzing medical images and documents to detect discrepancies and unreported findings, aiding in the early detection of cancer, heart diseases, and vascular diseases. The company has raised a total of $2.3 million to date.
Investment
growth-positive
האלגוריתם שיזהה מראש את הסרטן: הסטארטאפ IMedis גייס 1.3 מיליון דולר
Israeli company IMedis has raised $1.3 million in funding for its artificial intelligence-based system for early detection of cancer, heart disease, and blood diseases. The system combines image analysis with text analysis to alert radiologists in real-time to early signs of diseases that may not be evident in medical reports. IMedis aims to support radiologists in identifying specific clinical indications that may indicate cancer, heart disease, or blood diseases. The company faces competition from other AI-based medical imaging companies such as AIdoc, Zebra Medical, Viz.ai, and DiA Imaging. IMedis recently completed a clinical trial at UC San Diego Hospital, demonstrating the systems ability to improve patient care and reduce healthcare costs. The company has filed for a patent and is awaiting FDA approval.
Investment
IMedis Team
Employee Info
| Employees (range) | 500+ |
| Exact count | 1037 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
IMedis Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| BI Verification | Natalia Golczar |
| Registrar ID | 515774826 |
| Crunchbase | imedis-medical |
| Phone | +972768899800 |
| Creator | Vered Waxman |
| Creator email | vered.waxman@sncentral.org |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-08-30T00:00:00.000Z |
| Created | 2017-12-31T00:00:00.000Z |
| Claimed | Yes |